International Journal of Cardiology 181 (2015) 138–140
Contents lists available at ScienceDirect
International Journal of Cardiology journal homepage: www.elsevier.com/locate/ijcard
Letter to the Editor
A massive pericardial effusion in a cancer patient Pietro Pugliatti a,⁎, Rocco Donato b, Cesare de Gregorio a, Salvatore Patanè c a b c
Clinical and Experimental Department of Medicine and Pharmacology, University of Messina, Italy Department of Radiological Sciences, University of Messina, Italy Cardiologia Ospedale San Vincenzo — Taormina (Me) Azienda Sanitaria Provinciale di Messina, 98039 Taormina, Messina, Italy
a r t i c l e
i n f o
Conflict of interest The authors report no relationships that could be construed as a conflict of interest.
Article history: Received 18 November 2014 Accepted 23 November 2014 Available online 26 November 2014 Keywords: Echocardiography Pericardial effusion Computed tomography
Acknowledgements The authors of this manuscript have certified that they adhere to the statement of ethical publishing as appears in the International Journal of Cardiology. Author contributions: Pietro Pugliatti and Cesare de Gregorio prepared Fig. 1, Fig. 1 legend and the References; Rocco Donato prepared Fig. 2 and Fig. 2 legend; Pietro Pugliatti and Salvatore Patanè wrote the work. References
The progress in the cancer knowledge and treatment has led to a new frontier: the cardio-oncology [1–22]. Cancer patients can benefit from an open dialogue between both cardiologists and oncologists for the optimal effective patient's care [1–24]. Moreover oncosurgery represents a challenge for cardiologist [23] and preoperative cardiological assessment is the cornerstone of the modern oncosurgery as well as efficacious anesthesiological evaluation [23–25]. In the emerging scenario of concomitant problems and diseases [23–38], physicians should be familiar with available drugs, environmental epidemiology and patient factors [23–34] as well as with new emerging findings regarding use of cardiovascular drugs [26,27,30–33,39]. The pericardium is involved in a large number of systemic disorders including neoplastic pathologies [40–73]. We present a case of massive pericardial effusion in a 66-yearold Italian man suffering from a haematological cancer. Echocardiographic evaluation revealed a massive pericardial effusion with initial signs of atrial collapse (Fig. 1). Post-contrast CT images show a massive pericardial effusion (white asterisks), with left hilar lymphadenopathies, malignant lung nodules associated with mild pleural thickening and effusion (Fig. 2 Panel A) and abdominal voluminous lymphadenopathy (Fig. 2 Panel B). Also this case is illustrative of the benefit resulting from an open dialogue between both cardiologists and oncologists for the optimal effective patient's care. ⁎ Corresponding author at: Clinical and Experimental Department of Medicine and Pharmacology, University of Messina, 98124 Messina, Italy. E-mail address: [email protected] (P. Pugliatti).
http://dx.doi.org/10.1016/j.ijcard.2014.11.141 0167-5273/© 2014 Elsevier Ireland Ltd. All rights reserved.
[1] S. Patanè, A dark side of the cardio-oncology: the bacterial endocarditis prophylaxis, Int. J. Cardiol. 157 (3) (Jun 14 2012) 448–449, http://dx.doi.org/10.1016/j.ijcard. 2012.04.023 (Electronic publication ahead of print 2012 Apr 30). [2] E. Conti, A. Romiti, M.B. Musumeci, J. Passerini, L. Zezza, V. Mastromarino, C. D'Antonio, P. Marchetti, F. Paneni, C. Autore, M. Volpe, Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors, Int. J. Cardiol. 167 (6) (Sep 10 2013) 2421–2429 (Epub 2013 Feb 12). [3] S. Rateesh, S.A. Luis, C.R. Luis, B. Hughes, M. Nicolae, Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge? Int. J. Cardiol. 172 (2) (Mar 15 2014) e331–e333 (Epub 2014 Jan 10). [4] S. Kurisu, T. Iwasaki, K. Ishibashi, N. Mitsuba, Y. Dohi, Y. Kihara, Comparison of treatment and outcome of acute myocardial infarction between cancer patients and noncancer patients, Int. J. Cardiol. 167 (5) (Sep 1 2013) 2335–2337 (Epub 2012 Nov 30). [5] J.M. Scott, L.W. Jones, W.E. Hornsby, G.J. Koelwyn, M.G. Khouri, A.A. Joy, P.S. Douglas, S.G. Lakoski, Cancer therapy-induced autonomic dysfunction in early breast cancer: implications for aerobic exercise training, Int. J. Cardiol. 171 (2) (Feb 1 2014) e50–e51 (Epub 2013 Dec 7). [6] S. Claridge, A. Chakrabarti, K. Greaves, C.J. Boos, Successful use of trastuzumab following cardiac resynchronisation therapy, Int. J. Cardiol. 166 (2) (Jun 20 2013) e33–e34 (Epub 2013 Feb 18). [7] M. Lotrionte, G. Palazzoni, A. Abbate, E. De Marco, E. Mezzaroma, S. Di Persio, G. Frati, F. Loperfido, G. Biondi-Zoccai, Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin–Investigational chemotherapy–Tissue doppler imaging Evaluation) randomized pilot study, Int. J. Cardiol. 167 (3) (Aug 10 2013) 1055–1057 (Epub 2012 Nov 20). [8] M.G. Kaya, M. Ozkan, O. Gunebakmaz, H. Akkaya, E.G. Kaya, M. Akpek, N. Kalay, M. Dikilitas, M. Yarlioglues, H. Karaca, V. Berk, I. Ardic, A. Ergin, Y.Y. Lam, Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study, Int. J. Cardiol. 167 (5) (Sep 1 2013) 2306–2310 (Epub 2012 Jun 22). [9] K.L. Wang, C.J. Liu, T.F. Chao, C.M. Huang, C.H. Wu, T.J. Chen, C.E. Chiang, Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis, Int. J. Cardiol. 167 (5) (Sep 1 2013) 2162–2166 (Epub 2012 Jun 17).
P. Pugliatti et al. / International Journal of Cardiology 181 (2015) 138–140
Fig. 1. Echocardiographic evaluation revealed a massive pericardial effusion with initial signs of atrial collapse.
[10] S. Patanè, F. Marte, M. Sturiale, G. Dattilo, ST-segment elevation and diminution of prostate-specific antigen in a patient with coronary spasm and without significant coronary stenoses, Int. J. Cardiol. 148 (2) (Apr 14 2011) e31–e33 (Electronic publication ahead of print 2009 Mar 24). [11] S. Patanè, Is there a need for bacterial endocarditis prophylaxis in patients undergoing urological procedures? J. Cardiovasc. Transl. Res. 7 (3) (Apr 2014) 369–371 (Epub 2014 Feb 25). [12] S. Patanè, Is there a need for bacterial endocarditis prophylaxis in patients undergoing Gastrointestinal Endoscopy? J. Cardiovasc. Transl. Res. 7 (3) (Apr 2014) 372–374 (Epub 2014 Feb 25). [13] P. Pugliatti, C. De Gregorio, S. Patanè, The chance finding of echocardiographic complications of infective endocarditis, Int. J. Cardiol. 161 (3) (Nov 29 2012) e50–e51 (Epub 2012 Apr 30). [14] Y.F. Hu, C.J. Liu, P.M. Chang, H.M. Tsao, Y.J. Lin, S.L. Chang, L.W. Lo, T.C. Tuan, C.H. Li, T.F. Chao, F.P. Chung, J.N. Liao, T.J. Chen, S.A. Chen, Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients, Int. J. Cardiol. 165 (2) (May 10 2013) 355–357 (Epub 2012 Sep 16). [15] S. Patanè, Heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies, J. Card. Fail. 20 (6) (Jun 2014) 456–457 (Epub 2014 Apr 18). [16] S. Patanè, Insights into cardio-oncology: adrenergic receptor signaling and pathways in breast cancer, Curr. Med. Res. Opin. 26 (Jun 2014) 1–2.
139
[17] S. Patanè, Cardiotoxicity: cisplatin and long term cancer survivors, Int. J. Cardiol. 175 (1) (Jul 15 2014) 201–202 (Epub 2014 Apr 29). [18] P. Pugliatti, R. Donato, C. Zito, S. Carerj, S. Patanè, Cardioinhibitory vasovagal syncope in a cancer patient, Int. J. Cardiol. 174 (2) (Jun 15 2014) e64–e65 (Epub 2014 Apr 13). [19] P. Pugliatti, R. Donato, G. Di Bella, S. Carerj, S. Patanè, Contrast-enhancing right atrial thrombus in cancer patient, Int. J. Cardiol. 173 (3) (May 15 2014) e 35–e 37 (Epub 2014 Mar 15). [20] S. Patanè, F. Marte, Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system, Eur. Heart J. 30 (10) (May 2009) 1169–1170 (Epub 2009 Apr 10). [21] S. Patanè, Prostate-specific antigen kallikrein and the heart, World J. Cardiol. 1 (1) (Dec 31 2009) 23–25. [22] A. Budaj-Fidecka, M. Kurzyna, A. Fijałkowska, J. Żyłkowska, M. Wieteska, M. Florczyk, G. Szewczyk, A. Torbicki, K.J. Filipiak, G. Opolski, ZATPOL Registry Investigators, In-hospital major bleeding predicts mortality in patients with pulmonary embolism: an analysis of ZATPOL Registry data, Int. J. Cardiol. 168 (4) (Oct 9 2013) 3543–3549 (Epub 2013 May 24). [23] S. Patanè, A challenge in cardiology: the oncosurgery, Int. J. Cardiol. 174 (2) (Jun 15 2014) 411–412 (Epub 2014 Apr 13). [24] A.G. Shuman, B. Korc-Grodzicki, V. Shklar, F. Palmer, J.P. Shah, S.G. Patel, A new care paradigm in geriatric head and neck surgical oncology, J. Surg. Oncol. 108 (3) (Sep 2013) 187–191 (Epub 2013 Jun 27). [25] J. Zhao, X. Chu, Z. Xue, C. Xu, Retrospective analysis on risk factors of postoperative cardiac arrhythmia in 352 cases lung cancer with senile patients, Zhongguo Fei Ai Za Zhi 14 (3) (Mar 2011) 251–255 (Chinese). [26] S. Patanè, Cancer multidrug resistance-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs, Int. J. Cardiol. 176 (3) (Oct 20 2014) 1306–1308 (Epub 2014 Aug 2). [27] S. Patanè, HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs, Int. J. Cardiol. 176 (3) (Oct 20 2014) 1082–1085 (Epub 2014 Aug 2). [28] S. Patanè, Cardiotoxicity: anthracyclines and long term cancer survivors, Int. J. Cardiol. 176 (3) (Oct 20 2014) 1326–1328 (Epub 2014 Aug 4). [29] S. Patanè, Cardiotoxicity: trastuzumab and cancer survivors, Int. J Cardiol. 177 (2), Dec 15 (2014) 554–556. [30] S. Patanè, Ebola: is there a hope from treatment with cardiovascular drugs? Int J Cardiol 177 (2) (2014) 524–526. [31] S. Patanè, ERBB1/EGFR and ERBB2 (HER2/neu) — targeted therapies in cancer and cardiovascular system with cardiovascular drugs, Int. J. Cardiol. 176 (3) (Oct 20 2014) 1301–1303, http://dx.doi.org/10.1016/j.ijcard.2014.07.161 (Epub 2014 Aug 2). [32] S. Patanè, Is there a role for quinazoline-based α(1)-adrenoceptor antagonists in cardio-oncology? Cardiovasc. Drugs Ther. 28 (6) (December 2014) 587–588. [33] S. Patanè, The emerging scenario of the onco-cardiovascular patients, J. Cardiol. Ther. 1 (8) (2014) 141–149 (Available from: URL: http://www.ghrnet.org/index. php/jct/article/view/860/962). [34] E. Maseda, J. Mensa, J.C. Valía, J.I. Gomez-Herreras, F. Ramasco, E. Samso, M.A. Chiveli, J. Pereira, R. González, G. Aguilar, G. Tamayo, N. Ojeda, J. Rico, M.J. Gimenez, L. Aguilar, Bugs, hosts and ICU environment: countering pan-resistance in nosocomial microbiota and treating bacterial infections in the critical care setting, Rev. Esp. Quimioter. 26 (4) (Dec 2013) 312–331. [35] S. Patanè, Regulator of G-protein signaling 2 (RGS2) in cardiology and oncology, Int. J. Cardiol. 179 (January 20 2015) 63–65. [36] S. Patanè, M3 muscarinic acetylcholine receptor in cardiology and oncology, Int. J. Cardiol. 177 (2) (December 15 2014) 646–649.
Fig. 2. Panel A (four chamber view). Post-contrast CT images showed a massive pericardial effusion (white asterisks), with left hilar lymphadenopathies (black asterisks). Malignant lung nodules coexist (white arrows) associated with mild pleural thickening and effusion (white arrowheads). Panel B (short axis). Abdominal voluminous lymphadenopathy (black arrow).
140
P. Pugliatti et al. / International Journal of Cardiology 181 (2015) 138–140
[37] P. Pugliatti, A. Recupero, C. Zito, S. Patanè, The chance finding of an atrial septal defect in a cancer patient, Int. J. Cardiol. 177 (2) (December 15 2014) e68–e69. [38] S. Patanè, F. Marte, Prostate-specific antigen levels in hypertensive patients suffering from a non-ST elevation myocardial infarction or a new-onset atrial fibrillation, Int. J. Cardiol. 158 (3) (Jul 26 2012) 380–382 (Epub 2011 Feb 17). [39] R. La Rocca, G. Ferrari-Toninelli, S. Patanè, Widened QRS interval and left ventricular systolic depression after propafenone and promazine exposure, Int. J. Cardiol. 177 (1) (Nov 15 2014) 57–60. [40] S. Patanè, F. Marte, G. Di Bella, M. Davi', Pericardial effusion with elevated serum carbohydrate antigen 125 levels and ovarian tumor mass, Int. J. Cardiol. 127 (3) (Jul 21 2008) e105–e107 (Epub 2007 Apr 19). [41] M. Niemann, M. Hermann, S. Jacobs, A. Gotschy, S. Gordic, F.C. Tanner, R. Manka, The third ventricle — a case of a giant post infarct pseudoaneurysm, Int. J. Cardiol. 177 (3) (Dec 20 2014) e96–6. [42] C. Banfi, N. Rousse, F. Juthier, M. Midulla, I. Hysi, R.A. Guerbaai, A. Prat, P.V. Ennezat, A. Vincentelli, Successful repair despite late diagnosis of traumatic pericardial rupture with cardiac herniation, Int. J. Cardiol. 177 (3) (Dec 20 2014) e147–9. [43] T.H. Kim, J. Park, J.K. Park, J.S. Uhm, B. Joung, M.H. Lee, H.N. Pak, Pericardial fat volume is associated with clinical recurrence after catheter ablation for persistent atrial fibrillation, but not paroxysmal atrial fibrillation: an analysis of over 600-patients, Int. J. Cardiol. 176 (3) (Oct 20 2014) 841–846 (Epub 2014 Aug 8). [44] B. Berthoud, P.V. Ennezat, Electrical alternans due to large bilateral pleural effusion without pericardial effusion, Int. J. Cardiol. 176 (3) (Oct 20 2014) e125–e126 (Epub 2014 Aug 5). [45] V. Kytö, J. Sipilä, P. Rautava, Chronic constrictive pericarditis in general adult population, Int. J. Cardiol. 176 (3) (Oct 20 2014) 1158–1160 (Epub 2014 Aug 4). [46] P.C. Atallah, A. Kassier, S. Powers, IgG4-related disease with effusive-constrictive pericarditis, tamponade, and hepatopathy: a novel triad, Int. J. Cardiol. 176 (2) (Sep 20 2014) 516–518 (Epub 2014 Jul 12). [47] H. Kanazawa, H. Yamabe, K. Enomoto, J. Koyama, K. Morihisa, T. Hoshiyama, K. Matsui, H. Ogawa, Importance of pericardial fat in the formation of complex fractionated atrial electrogram region in atrial fibrillation, Int. J. Cardiol. 174 (3) (Jul 1 2014) 557–564 (Epub 2014 Apr 21). [48] C. Prat-Vidal, C. Gálvez-Montón, V. Puig-Sanvicens, B. Sanchez, I. Díaz-Güemes, P. Bogónez-Franco, I. Perea-Gil, A. Casas-Solà, S. Roura, A. Llucià-Valldeperas, C. Soler-Botija, F.M. Sánchez-Margallo, C.E. Semino, R. Bragos, A. Bayes-Genis, Online monitoring of myocardial bioprosthesis for cardiac repair, Int. J. Cardiol. 174 (3) (Jul 1 2014) 654–661 (Epub 2014 Apr 26). [49] X. Freixa, A. Abualsaud, J. Chan, M. Nosair, A. Tzikas, P. Garceau, A. Basmadjian, R. Ibrahim, Left atrial appendage occlusion: initial experience with the Amplatzer™ Amulet™, Int. J. Cardiol. 174 (3) (Jul 1 2014) 492–496 (Epub 2014 Mar 28). [50] A. Palazzuoli, M.A. Mazzei, G. Ruocco, L. Volterrani, Constrictive pericarditis in Erdheim–Chester disease: an integrated echocardiographic and magnetic resonance approach, Int. J. Cardiol. 174 (2) (Jun 15 2014) e38–e41 (Epub 2014 Apr 15). [51] K. Gatzoulis, S. Archontakis, D. Tsiachris, G. Lazaros, T. Apostolopoulos, G. Zervopoulos, X. Costeas, P. Dilaveris, S. Sideris, I. Kallikazaros, C. Stefanadis, Post-cardiac injury syndrome after permanent electronic cardiac device implantation. Incidence, presentation, management and long-term prognosis, Int. J. Cardiol. 174 (1) (Jun 1 2014) 163–164 (Epub 2014 Apr 2). [52] G.B. Kim, H.G. Lim, Y.J. Kim, E.Y. Choi, B.S. Kwon, S. Jeong, Novel self-expandable, stent-based transcatheter pulmonic valve: a preclinical animal study, Int. J. Cardiol. 173 (1) (Apr 15 2014) 74–79 (Epub 2014 Feb 20). [53] P.C. Oh, S.H. Han, K.K. Koh, Reply to comment on: idiopathic pericarditis presenting large hemorrhagic pericardial effusion by Dr. George A Lazaros, Int. J. Cardiol. 172 (1) (Mar 1 2014) 250 (Epub 2014 Jan 10). [54] P. Ungprasert, T. Wannarong, T. Panichsillapakit, W. Cheungpasitporn, C. Thongprayoon, S. Ahmed, D.A. Raddatz, Cardiac involvement in mixed connective tissue disease: a systematic review, Int. J. Cardiol. 171 (3) (Feb 15 2014) 326–330 (Epub 2013 Dec 29).
[55] J.P. Sun, A.P. Lee, X.S. Yang, C.M. Yu, Doppler flow signals in small amount pericardial effusion after radiofrequency ablation, Int. J. Cardiol. 171 (3) (Feb 15 2014) 447–448 (Epub 2013 Dec 4). [56] G. Lazaros, C. Stefanadis, Comment on: idiopathic pericarditis presenting large hemorrhagic pericardial effusion, Int. J. Cardiol. 171 (2) (Feb 1 2014) 301 (Epub 2013 Dec 3). [57] S. Lim, J.B. Meigs, Ectopic fat and cardiometabolic and vascular risk, Int. J. Cardiol. 169 (3) (Nov 5 2014) 166–176 (Epub 2013 Sep 7, in review). [58] M. Shurrab, A. Danon, I. Lashevsky, A. Kiss, D. Newman, T. Szili-Torok, E. Crystal, Robotically assisted ablation of atrial fibrillation: a systematic review and metaanalysis, Int. J. Cardiol. 169 (3) (Nov 5 2014) 157–165 (Epub 2013 Sep 10, in review). [59] G.D. Katritsis, G.C. Siontis, E. Giazitzoglou, N. Fragakis, D.G. Katritsis, Complications of transseptal catheterization for different cardiac procedures, Int. J. Cardiol. 168 (6) (Oct 15 2013) 5352–5354 (Epub 2013 Aug 14). [60] P.C. Oh, S.J. Baek, J. Moon, S.H. Han, K.Y. Park, K.K. Koh, Idiopathic pericarditis presenting large hemorrhagic pericardial effusion, Int. J. Cardiol. 168 (4) (Oct 9 2013) 4467–4469 (Epub 2013 Jul 19). [61] C. Lawley, J. Mazhar, S.M. Grieve, G.A. Figtree, Visualizing pericardial inflammation in Dressler's syndrome with cardiac magnetic resonance imaging, Int. J. Cardiol. 168 (1) (Sep 20 2013) e32–e33 (Epub 2013 Jun 14). [62] E.Y. Kim, K.Y. Park, Y.B. Jeon, S.Y. Ha, W.J. Chung, A primary pericardial liposarcoma mimicking intracardiac neoplasm on echocardiography: role of computed tomography and magnetic resonance imaging in the differential diagnosis, Int. J. Cardiol. 167 (4) (Aug 20 2013) e92–e94 (Epub 2013 May 6). [63] C. Barcin, E. Yalcinkaya, H.K. Kabul, Cholesterol pericarditis associated with rheumatoid arthritis: a rare cause of pericardial effusion, Int. J. Cardiol. 166 (3) (Jul 1 2013) e 56–e 58 (Epub 2013 Feb 11). [64] J.G. Mirelis, A. Garcia-Alvarez, L. Fernandez-Friera, S. Sawit, R. Hinojar, V. Fuster, M.J. García, J. Sanz, Respiratory ventricular area changes measured with real-time cardiac magnetic resonance: a new, accurate, and reproducible approach for the diagnosis of pericardial constriction, Int. J. Cardiol. 166 (1) (Jun 5 2013) 267–271 (Epub 2012 Oct 3). [65] M. Imazio, B.D. Hoit, Post-cardiac injury syndromes. An emerging cause of pericardial diseases, Int. J. Cardiol. 168 (2) (Sep 30 2014) 648–652 (Epub 2012 Oct 3, in review). [66] T. Ito, Y. Suzuki, M. Ehara, H. Matsuo, T. Teramoto, M. Terashima, K. Nasu, Y. Kinoshita, E. Tsuchikane, T. Suzuki, G. Kimura, Impact of epicardial fat volume on coronary artery disease in symptomatic patients with a zero calcium score, Int. J. Cardiol. 167 (6) (Sep 10 2013) 2852–2858 (Epub 2012 Aug 9). [67] A. Lamari, G. Dattilo, D. Tulino, F. Marte, S. Patanè, Definitive diagnosis of Hashitoxicosis with pericardial effusion, Int. J. Cardiol. 145 (3) (Dec 3 2010) 506 (Epub 2010 Jan 3). [68] R. La Rocca, V. Materia, A. Pasquini, F.C. La Rosa, F. Marte, S. Patanè, T-wave inversion after a severe head injury without ischemic heart disease, Int. J. Cardiol. 151 (2) (Sep 1 2011) e43–e44 (Epub 2009 Dec 29). [69] A. Lamari, G. Dattilo, D. Tulino, F. Marte, S. Patanè, Hashitoxicosis with pericardial effusion, Int. J. Cardiol. 145 (2) (Nov 19 2010) e77–e79 (Epub 2009 Apr 28). [70] G. Dattilo, S. Crosca, S. Tavella, F. Marte, S. Patanè, Pericardial effusion associated with subclinical hypothyroidism, Int. J. Cardiol. 153 (3) (Dec 15 2011) e47–e50 (Epub 2009 Apr 18). [71] S. Patanè, F. Marte, M. Sturiale, G. Dattilo, F. Luzza, Atrial flutter, ventricular tachycardia and changing axis deviation associated with scleroderma, Int. J. Cardiol. 153 (2) (Dec 1 2011) e25–e28 (Epub 2009 Apr 8). [72] G. Dattilo, D. Tulino, V. Tulino, A. Lamari, F. Marte, S. Patanè, The chance finding of an aneurysm of the right sinus of Valsalva in an 11-year-old child with a ventricular septal defect and a pericardial effusion, Int. J. Cardiol. 151 (3) (Sep 15 2011) e77–e79 (Epub 2009 Apr 3). [73] X. Liu,, Y. Feng, G. Xu, Y. Zhang, J. Qian, H. Deng, R. Guo, A new strategy for pericardiocentesis with a visual puncture system: the feasibility and efficiency study in a pericardial effusion model, Int. J. Cardiol. 177 (3) (December 20 2014) e128–30.
Contents lists available at ScienceDirect
International Journal of Cardiology journal homepage: www.elsevier.com/locate/ijcard
Letter to the Editor
A massive pericardial effusion in a cancer patient Pietro Pugliatti a,⁎, Rocco Donato b, Cesare de Gregorio a, Salvatore Patanè c a b c
Clinical and Experimental Department of Medicine and Pharmacology, University of Messina, Italy Department of Radiological Sciences, University of Messina, Italy Cardiologia Ospedale San Vincenzo — Taormina (Me) Azienda Sanitaria Provinciale di Messina, 98039 Taormina, Messina, Italy
a r t i c l e
i n f o
Conflict of interest The authors report no relationships that could be construed as a conflict of interest.
Article history: Received 18 November 2014 Accepted 23 November 2014 Available online 26 November 2014 Keywords: Echocardiography Pericardial effusion Computed tomography
Acknowledgements The authors of this manuscript have certified that they adhere to the statement of ethical publishing as appears in the International Journal of Cardiology. Author contributions: Pietro Pugliatti and Cesare de Gregorio prepared Fig. 1, Fig. 1 legend and the References; Rocco Donato prepared Fig. 2 and Fig. 2 legend; Pietro Pugliatti and Salvatore Patanè wrote the work. References
The progress in the cancer knowledge and treatment has led to a new frontier: the cardio-oncology [1–22]. Cancer patients can benefit from an open dialogue between both cardiologists and oncologists for the optimal effective patient's care [1–24]. Moreover oncosurgery represents a challenge for cardiologist [23] and preoperative cardiological assessment is the cornerstone of the modern oncosurgery as well as efficacious anesthesiological evaluation [23–25]. In the emerging scenario of concomitant problems and diseases [23–38], physicians should be familiar with available drugs, environmental epidemiology and patient factors [23–34] as well as with new emerging findings regarding use of cardiovascular drugs [26,27,30–33,39]. The pericardium is involved in a large number of systemic disorders including neoplastic pathologies [40–73]. We present a case of massive pericardial effusion in a 66-yearold Italian man suffering from a haematological cancer. Echocardiographic evaluation revealed a massive pericardial effusion with initial signs of atrial collapse (Fig. 1). Post-contrast CT images show a massive pericardial effusion (white asterisks), with left hilar lymphadenopathies, malignant lung nodules associated with mild pleural thickening and effusion (Fig. 2 Panel A) and abdominal voluminous lymphadenopathy (Fig. 2 Panel B). Also this case is illustrative of the benefit resulting from an open dialogue between both cardiologists and oncologists for the optimal effective patient's care. ⁎ Corresponding author at: Clinical and Experimental Department of Medicine and Pharmacology, University of Messina, 98124 Messina, Italy. E-mail address: [email protected] (P. Pugliatti).
http://dx.doi.org/10.1016/j.ijcard.2014.11.141 0167-5273/© 2014 Elsevier Ireland Ltd. All rights reserved.
[1] S. Patanè, A dark side of the cardio-oncology: the bacterial endocarditis prophylaxis, Int. J. Cardiol. 157 (3) (Jun 14 2012) 448–449, http://dx.doi.org/10.1016/j.ijcard. 2012.04.023 (Electronic publication ahead of print 2012 Apr 30). [2] E. Conti, A. Romiti, M.B. Musumeci, J. Passerini, L. Zezza, V. Mastromarino, C. D'Antonio, P. Marchetti, F. Paneni, C. Autore, M. Volpe, Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors, Int. J. Cardiol. 167 (6) (Sep 10 2013) 2421–2429 (Epub 2013 Feb 12). [3] S. Rateesh, S.A. Luis, C.R. Luis, B. Hughes, M. Nicolae, Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge? Int. J. Cardiol. 172 (2) (Mar 15 2014) e331–e333 (Epub 2014 Jan 10). [4] S. Kurisu, T. Iwasaki, K. Ishibashi, N. Mitsuba, Y. Dohi, Y. Kihara, Comparison of treatment and outcome of acute myocardial infarction between cancer patients and noncancer patients, Int. J. Cardiol. 167 (5) (Sep 1 2013) 2335–2337 (Epub 2012 Nov 30). [5] J.M. Scott, L.W. Jones, W.E. Hornsby, G.J. Koelwyn, M.G. Khouri, A.A. Joy, P.S. Douglas, S.G. Lakoski, Cancer therapy-induced autonomic dysfunction in early breast cancer: implications for aerobic exercise training, Int. J. Cardiol. 171 (2) (Feb 1 2014) e50–e51 (Epub 2013 Dec 7). [6] S. Claridge, A. Chakrabarti, K. Greaves, C.J. Boos, Successful use of trastuzumab following cardiac resynchronisation therapy, Int. J. Cardiol. 166 (2) (Jun 20 2013) e33–e34 (Epub 2013 Feb 18). [7] M. Lotrionte, G. Palazzoni, A. Abbate, E. De Marco, E. Mezzaroma, S. Di Persio, G. Frati, F. Loperfido, G. Biondi-Zoccai, Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin–Investigational chemotherapy–Tissue doppler imaging Evaluation) randomized pilot study, Int. J. Cardiol. 167 (3) (Aug 10 2013) 1055–1057 (Epub 2012 Nov 20). [8] M.G. Kaya, M. Ozkan, O. Gunebakmaz, H. Akkaya, E.G. Kaya, M. Akpek, N. Kalay, M. Dikilitas, M. Yarlioglues, H. Karaca, V. Berk, I. Ardic, A. Ergin, Y.Y. Lam, Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study, Int. J. Cardiol. 167 (5) (Sep 1 2013) 2306–2310 (Epub 2012 Jun 22). [9] K.L. Wang, C.J. Liu, T.F. Chao, C.M. Huang, C.H. Wu, T.J. Chen, C.E. Chiang, Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis, Int. J. Cardiol. 167 (5) (Sep 1 2013) 2162–2166 (Epub 2012 Jun 17).
P. Pugliatti et al. / International Journal of Cardiology 181 (2015) 138–140
Fig. 1. Echocardiographic evaluation revealed a massive pericardial effusion with initial signs of atrial collapse.
[10] S. Patanè, F. Marte, M. Sturiale, G. Dattilo, ST-segment elevation and diminution of prostate-specific antigen in a patient with coronary spasm and without significant coronary stenoses, Int. J. Cardiol. 148 (2) (Apr 14 2011) e31–e33 (Electronic publication ahead of print 2009 Mar 24). [11] S. Patanè, Is there a need for bacterial endocarditis prophylaxis in patients undergoing urological procedures? J. Cardiovasc. Transl. Res. 7 (3) (Apr 2014) 369–371 (Epub 2014 Feb 25). [12] S. Patanè, Is there a need for bacterial endocarditis prophylaxis in patients undergoing Gastrointestinal Endoscopy? J. Cardiovasc. Transl. Res. 7 (3) (Apr 2014) 372–374 (Epub 2014 Feb 25). [13] P. Pugliatti, C. De Gregorio, S. Patanè, The chance finding of echocardiographic complications of infective endocarditis, Int. J. Cardiol. 161 (3) (Nov 29 2012) e50–e51 (Epub 2012 Apr 30). [14] Y.F. Hu, C.J. Liu, P.M. Chang, H.M. Tsao, Y.J. Lin, S.L. Chang, L.W. Lo, T.C. Tuan, C.H. Li, T.F. Chao, F.P. Chung, J.N. Liao, T.J. Chen, S.A. Chen, Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients, Int. J. Cardiol. 165 (2) (May 10 2013) 355–357 (Epub 2012 Sep 16). [15] S. Patanè, Heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies, J. Card. Fail. 20 (6) (Jun 2014) 456–457 (Epub 2014 Apr 18). [16] S. Patanè, Insights into cardio-oncology: adrenergic receptor signaling and pathways in breast cancer, Curr. Med. Res. Opin. 26 (Jun 2014) 1–2.
139
[17] S. Patanè, Cardiotoxicity: cisplatin and long term cancer survivors, Int. J. Cardiol. 175 (1) (Jul 15 2014) 201–202 (Epub 2014 Apr 29). [18] P. Pugliatti, R. Donato, C. Zito, S. Carerj, S. Patanè, Cardioinhibitory vasovagal syncope in a cancer patient, Int. J. Cardiol. 174 (2) (Jun 15 2014) e64–e65 (Epub 2014 Apr 13). [19] P. Pugliatti, R. Donato, G. Di Bella, S. Carerj, S. Patanè, Contrast-enhancing right atrial thrombus in cancer patient, Int. J. Cardiol. 173 (3) (May 15 2014) e 35–e 37 (Epub 2014 Mar 15). [20] S. Patanè, F. Marte, Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system, Eur. Heart J. 30 (10) (May 2009) 1169–1170 (Epub 2009 Apr 10). [21] S. Patanè, Prostate-specific antigen kallikrein and the heart, World J. Cardiol. 1 (1) (Dec 31 2009) 23–25. [22] A. Budaj-Fidecka, M. Kurzyna, A. Fijałkowska, J. Żyłkowska, M. Wieteska, M. Florczyk, G. Szewczyk, A. Torbicki, K.J. Filipiak, G. Opolski, ZATPOL Registry Investigators, In-hospital major bleeding predicts mortality in patients with pulmonary embolism: an analysis of ZATPOL Registry data, Int. J. Cardiol. 168 (4) (Oct 9 2013) 3543–3549 (Epub 2013 May 24). [23] S. Patanè, A challenge in cardiology: the oncosurgery, Int. J. Cardiol. 174 (2) (Jun 15 2014) 411–412 (Epub 2014 Apr 13). [24] A.G. Shuman, B. Korc-Grodzicki, V. Shklar, F. Palmer, J.P. Shah, S.G. Patel, A new care paradigm in geriatric head and neck surgical oncology, J. Surg. Oncol. 108 (3) (Sep 2013) 187–191 (Epub 2013 Jun 27). [25] J. Zhao, X. Chu, Z. Xue, C. Xu, Retrospective analysis on risk factors of postoperative cardiac arrhythmia in 352 cases lung cancer with senile patients, Zhongguo Fei Ai Za Zhi 14 (3) (Mar 2011) 251–255 (Chinese). [26] S. Patanè, Cancer multidrug resistance-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs, Int. J. Cardiol. 176 (3) (Oct 20 2014) 1306–1308 (Epub 2014 Aug 2). [27] S. Patanè, HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs, Int. J. Cardiol. 176 (3) (Oct 20 2014) 1082–1085 (Epub 2014 Aug 2). [28] S. Patanè, Cardiotoxicity: anthracyclines and long term cancer survivors, Int. J. Cardiol. 176 (3) (Oct 20 2014) 1326–1328 (Epub 2014 Aug 4). [29] S. Patanè, Cardiotoxicity: trastuzumab and cancer survivors, Int. J Cardiol. 177 (2), Dec 15 (2014) 554–556. [30] S. Patanè, Ebola: is there a hope from treatment with cardiovascular drugs? Int J Cardiol 177 (2) (2014) 524–526. [31] S. Patanè, ERBB1/EGFR and ERBB2 (HER2/neu) — targeted therapies in cancer and cardiovascular system with cardiovascular drugs, Int. J. Cardiol. 176 (3) (Oct 20 2014) 1301–1303, http://dx.doi.org/10.1016/j.ijcard.2014.07.161 (Epub 2014 Aug 2). [32] S. Patanè, Is there a role for quinazoline-based α(1)-adrenoceptor antagonists in cardio-oncology? Cardiovasc. Drugs Ther. 28 (6) (December 2014) 587–588. [33] S. Patanè, The emerging scenario of the onco-cardiovascular patients, J. Cardiol. Ther. 1 (8) (2014) 141–149 (Available from: URL: http://www.ghrnet.org/index. php/jct/article/view/860/962). [34] E. Maseda, J. Mensa, J.C. Valía, J.I. Gomez-Herreras, F. Ramasco, E. Samso, M.A. Chiveli, J. Pereira, R. González, G. Aguilar, G. Tamayo, N. Ojeda, J. Rico, M.J. Gimenez, L. Aguilar, Bugs, hosts and ICU environment: countering pan-resistance in nosocomial microbiota and treating bacterial infections in the critical care setting, Rev. Esp. Quimioter. 26 (4) (Dec 2013) 312–331. [35] S. Patanè, Regulator of G-protein signaling 2 (RGS2) in cardiology and oncology, Int. J. Cardiol. 179 (January 20 2015) 63–65. [36] S. Patanè, M3 muscarinic acetylcholine receptor in cardiology and oncology, Int. J. Cardiol. 177 (2) (December 15 2014) 646–649.
Fig. 2. Panel A (four chamber view). Post-contrast CT images showed a massive pericardial effusion (white asterisks), with left hilar lymphadenopathies (black asterisks). Malignant lung nodules coexist (white arrows) associated with mild pleural thickening and effusion (white arrowheads). Panel B (short axis). Abdominal voluminous lymphadenopathy (black arrow).
140
P. Pugliatti et al. / International Journal of Cardiology 181 (2015) 138–140
[37] P. Pugliatti, A. Recupero, C. Zito, S. Patanè, The chance finding of an atrial septal defect in a cancer patient, Int. J. Cardiol. 177 (2) (December 15 2014) e68–e69. [38] S. Patanè, F. Marte, Prostate-specific antigen levels in hypertensive patients suffering from a non-ST elevation myocardial infarction or a new-onset atrial fibrillation, Int. J. Cardiol. 158 (3) (Jul 26 2012) 380–382 (Epub 2011 Feb 17). [39] R. La Rocca, G. Ferrari-Toninelli, S. Patanè, Widened QRS interval and left ventricular systolic depression after propafenone and promazine exposure, Int. J. Cardiol. 177 (1) (Nov 15 2014) 57–60. [40] S. Patanè, F. Marte, G. Di Bella, M. Davi', Pericardial effusion with elevated serum carbohydrate antigen 125 levels and ovarian tumor mass, Int. J. Cardiol. 127 (3) (Jul 21 2008) e105–e107 (Epub 2007 Apr 19). [41] M. Niemann, M. Hermann, S. Jacobs, A. Gotschy, S. Gordic, F.C. Tanner, R. Manka, The third ventricle — a case of a giant post infarct pseudoaneurysm, Int. J. Cardiol. 177 (3) (Dec 20 2014) e96–6. [42] C. Banfi, N. Rousse, F. Juthier, M. Midulla, I. Hysi, R.A. Guerbaai, A. Prat, P.V. Ennezat, A. Vincentelli, Successful repair despite late diagnosis of traumatic pericardial rupture with cardiac herniation, Int. J. Cardiol. 177 (3) (Dec 20 2014) e147–9. [43] T.H. Kim, J. Park, J.K. Park, J.S. Uhm, B. Joung, M.H. Lee, H.N. Pak, Pericardial fat volume is associated with clinical recurrence after catheter ablation for persistent atrial fibrillation, but not paroxysmal atrial fibrillation: an analysis of over 600-patients, Int. J. Cardiol. 176 (3) (Oct 20 2014) 841–846 (Epub 2014 Aug 8). [44] B. Berthoud, P.V. Ennezat, Electrical alternans due to large bilateral pleural effusion without pericardial effusion, Int. J. Cardiol. 176 (3) (Oct 20 2014) e125–e126 (Epub 2014 Aug 5). [45] V. Kytö, J. Sipilä, P. Rautava, Chronic constrictive pericarditis in general adult population, Int. J. Cardiol. 176 (3) (Oct 20 2014) 1158–1160 (Epub 2014 Aug 4). [46] P.C. Atallah, A. Kassier, S. Powers, IgG4-related disease with effusive-constrictive pericarditis, tamponade, and hepatopathy: a novel triad, Int. J. Cardiol. 176 (2) (Sep 20 2014) 516–518 (Epub 2014 Jul 12). [47] H. Kanazawa, H. Yamabe, K. Enomoto, J. Koyama, K. Morihisa, T. Hoshiyama, K. Matsui, H. Ogawa, Importance of pericardial fat in the formation of complex fractionated atrial electrogram region in atrial fibrillation, Int. J. Cardiol. 174 (3) (Jul 1 2014) 557–564 (Epub 2014 Apr 21). [48] C. Prat-Vidal, C. Gálvez-Montón, V. Puig-Sanvicens, B. Sanchez, I. Díaz-Güemes, P. Bogónez-Franco, I. Perea-Gil, A. Casas-Solà, S. Roura, A. Llucià-Valldeperas, C. Soler-Botija, F.M. Sánchez-Margallo, C.E. Semino, R. Bragos, A. Bayes-Genis, Online monitoring of myocardial bioprosthesis for cardiac repair, Int. J. Cardiol. 174 (3) (Jul 1 2014) 654–661 (Epub 2014 Apr 26). [49] X. Freixa, A. Abualsaud, J. Chan, M. Nosair, A. Tzikas, P. Garceau, A. Basmadjian, R. Ibrahim, Left atrial appendage occlusion: initial experience with the Amplatzer™ Amulet™, Int. J. Cardiol. 174 (3) (Jul 1 2014) 492–496 (Epub 2014 Mar 28). [50] A. Palazzuoli, M.A. Mazzei, G. Ruocco, L. Volterrani, Constrictive pericarditis in Erdheim–Chester disease: an integrated echocardiographic and magnetic resonance approach, Int. J. Cardiol. 174 (2) (Jun 15 2014) e38–e41 (Epub 2014 Apr 15). [51] K. Gatzoulis, S. Archontakis, D. Tsiachris, G. Lazaros, T. Apostolopoulos, G. Zervopoulos, X. Costeas, P. Dilaveris, S. Sideris, I. Kallikazaros, C. Stefanadis, Post-cardiac injury syndrome after permanent electronic cardiac device implantation. Incidence, presentation, management and long-term prognosis, Int. J. Cardiol. 174 (1) (Jun 1 2014) 163–164 (Epub 2014 Apr 2). [52] G.B. Kim, H.G. Lim, Y.J. Kim, E.Y. Choi, B.S. Kwon, S. Jeong, Novel self-expandable, stent-based transcatheter pulmonic valve: a preclinical animal study, Int. J. Cardiol. 173 (1) (Apr 15 2014) 74–79 (Epub 2014 Feb 20). [53] P.C. Oh, S.H. Han, K.K. Koh, Reply to comment on: idiopathic pericarditis presenting large hemorrhagic pericardial effusion by Dr. George A Lazaros, Int. J. Cardiol. 172 (1) (Mar 1 2014) 250 (Epub 2014 Jan 10). [54] P. Ungprasert, T. Wannarong, T. Panichsillapakit, W. Cheungpasitporn, C. Thongprayoon, S. Ahmed, D.A. Raddatz, Cardiac involvement in mixed connective tissue disease: a systematic review, Int. J. Cardiol. 171 (3) (Feb 15 2014) 326–330 (Epub 2013 Dec 29).
[55] J.P. Sun, A.P. Lee, X.S. Yang, C.M. Yu, Doppler flow signals in small amount pericardial effusion after radiofrequency ablation, Int. J. Cardiol. 171 (3) (Feb 15 2014) 447–448 (Epub 2013 Dec 4). [56] G. Lazaros, C. Stefanadis, Comment on: idiopathic pericarditis presenting large hemorrhagic pericardial effusion, Int. J. Cardiol. 171 (2) (Feb 1 2014) 301 (Epub 2013 Dec 3). [57] S. Lim, J.B. Meigs, Ectopic fat and cardiometabolic and vascular risk, Int. J. Cardiol. 169 (3) (Nov 5 2014) 166–176 (Epub 2013 Sep 7, in review). [58] M. Shurrab, A. Danon, I. Lashevsky, A. Kiss, D. Newman, T. Szili-Torok, E. Crystal, Robotically assisted ablation of atrial fibrillation: a systematic review and metaanalysis, Int. J. Cardiol. 169 (3) (Nov 5 2014) 157–165 (Epub 2013 Sep 10, in review). [59] G.D. Katritsis, G.C. Siontis, E. Giazitzoglou, N. Fragakis, D.G. Katritsis, Complications of transseptal catheterization for different cardiac procedures, Int. J. Cardiol. 168 (6) (Oct 15 2013) 5352–5354 (Epub 2013 Aug 14). [60] P.C. Oh, S.J. Baek, J. Moon, S.H. Han, K.Y. Park, K.K. Koh, Idiopathic pericarditis presenting large hemorrhagic pericardial effusion, Int. J. Cardiol. 168 (4) (Oct 9 2013) 4467–4469 (Epub 2013 Jul 19). [61] C. Lawley, J. Mazhar, S.M. Grieve, G.A. Figtree, Visualizing pericardial inflammation in Dressler's syndrome with cardiac magnetic resonance imaging, Int. J. Cardiol. 168 (1) (Sep 20 2013) e32–e33 (Epub 2013 Jun 14). [62] E.Y. Kim, K.Y. Park, Y.B. Jeon, S.Y. Ha, W.J. Chung, A primary pericardial liposarcoma mimicking intracardiac neoplasm on echocardiography: role of computed tomography and magnetic resonance imaging in the differential diagnosis, Int. J. Cardiol. 167 (4) (Aug 20 2013) e92–e94 (Epub 2013 May 6). [63] C. Barcin, E. Yalcinkaya, H.K. Kabul, Cholesterol pericarditis associated with rheumatoid arthritis: a rare cause of pericardial effusion, Int. J. Cardiol. 166 (3) (Jul 1 2013) e 56–e 58 (Epub 2013 Feb 11). [64] J.G. Mirelis, A. Garcia-Alvarez, L. Fernandez-Friera, S. Sawit, R. Hinojar, V. Fuster, M.J. García, J. Sanz, Respiratory ventricular area changes measured with real-time cardiac magnetic resonance: a new, accurate, and reproducible approach for the diagnosis of pericardial constriction, Int. J. Cardiol. 166 (1) (Jun 5 2013) 267–271 (Epub 2012 Oct 3). [65] M. Imazio, B.D. Hoit, Post-cardiac injury syndromes. An emerging cause of pericardial diseases, Int. J. Cardiol. 168 (2) (Sep 30 2014) 648–652 (Epub 2012 Oct 3, in review). [66] T. Ito, Y. Suzuki, M. Ehara, H. Matsuo, T. Teramoto, M. Terashima, K. Nasu, Y. Kinoshita, E. Tsuchikane, T. Suzuki, G. Kimura, Impact of epicardial fat volume on coronary artery disease in symptomatic patients with a zero calcium score, Int. J. Cardiol. 167 (6) (Sep 10 2013) 2852–2858 (Epub 2012 Aug 9). [67] A. Lamari, G. Dattilo, D. Tulino, F. Marte, S. Patanè, Definitive diagnosis of Hashitoxicosis with pericardial effusion, Int. J. Cardiol. 145 (3) (Dec 3 2010) 506 (Epub 2010 Jan 3). [68] R. La Rocca, V. Materia, A. Pasquini, F.C. La Rosa, F. Marte, S. Patanè, T-wave inversion after a severe head injury without ischemic heart disease, Int. J. Cardiol. 151 (2) (Sep 1 2011) e43–e44 (Epub 2009 Dec 29). [69] A. Lamari, G. Dattilo, D. Tulino, F. Marte, S. Patanè, Hashitoxicosis with pericardial effusion, Int. J. Cardiol. 145 (2) (Nov 19 2010) e77–e79 (Epub 2009 Apr 28). [70] G. Dattilo, S. Crosca, S. Tavella, F. Marte, S. Patanè, Pericardial effusion associated with subclinical hypothyroidism, Int. J. Cardiol. 153 (3) (Dec 15 2011) e47–e50 (Epub 2009 Apr 18). [71] S. Patanè, F. Marte, M. Sturiale, G. Dattilo, F. Luzza, Atrial flutter, ventricular tachycardia and changing axis deviation associated with scleroderma, Int. J. Cardiol. 153 (2) (Dec 1 2011) e25–e28 (Epub 2009 Apr 8). [72] G. Dattilo, D. Tulino, V. Tulino, A. Lamari, F. Marte, S. Patanè, The chance finding of an aneurysm of the right sinus of Valsalva in an 11-year-old child with a ventricular septal defect and a pericardial effusion, Int. J. Cardiol. 151 (3) (Sep 15 2011) e77–e79 (Epub 2009 Apr 3). [73] X. Liu,, Y. Feng, G. Xu, Y. Zhang, J. Qian, H. Deng, R. Guo, A new strategy for pericardiocentesis with a visual puncture system: the feasibility and efficiency study in a pericardial effusion model, Int. J. Cardiol. 177 (3) (December 20 2014) e128–30.
